- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04528056
Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension
August 22, 2020 updated by: RenJi Hospital
Under placebo control, the investigators intend to evaluate the effectiveness and safety of anti-inflammatory therapy and/or targeted drug therapy for early treatment of patients with pulmonary arterial hypertension.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Pulmonary arterial hypertension is characterized by decompensated increase of pulmonary artery pressure owing to continuous progression of pulmonary vascular resistance and can ultimately cause right heart failure even death.
At present, the treatment of pulmonary arterial hypertension is mainly the application of specific drug therapy.
Specific drug therapy involves the three major pathways of endothelin, nitric oxide and prostacyclin.
The main mechanisms of vasodilation and anti-proliferation are used to treat pulmonary arterial hypertension.
However, the price of specific drug therapy is too expensive, which puts huge financial pressure on patients.
Evidence shows that inflammation exists in the early stages of pulmonary arterial hypertension and anti-inflammatory treatment is effective in animal experiments.
Under placebo control, the investigators intend to evaluate the effectiveness and safety of anti-inflammatory therapy and/or targeted drug therapy for early treatment of patients with pulmonary arterial hypertension.
Study Type
Interventional
Enrollment (Anticipated)
80
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jieyan Shen, PhD
- Phone Number: +8613701864819
- Email: shenjieyan@renji.com
Study Locations
-
-
-
Shanghai, China, 200127
- Recruiting
- RenJi hospital
-
Contact:
- Jian Wang, postgraduate
- Phone Number: +8613780172992
- Email: wangjian_ky@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Pulmonary artery systolic pressure estimated in the most recent echocardiography examination before screening ≧40mmHg.
- Before the study, subjects received the best traditional pulmonary arterial hypertension(PAH) treatment (such as oral Ca2+ antagonists, oxygen therapy, digoxin, diuretics, and anticoagulants), and no increase, discontinuation, or dose change at least one month before randomization. But it is allowed to stop or adjust anticoagulants, and adjust the therapeutic dose of diuretics.
- The results of echocardiography showed that the systolic and diastolic functions of the left ventricle were normal, and there was no clinically significant left heart disease (such as mitral valve disease).
Exclusion Criteria:
- Patients who have received endothelin receptor antagonists and anti-inflammatory drugs within 30 days before randomization.
- Patients with changes in the basic PAH treatment within one month before randomization (such as addition/removal of therapeutic drugs or dose adjustment; including but not limited to oxygen, diuretics, digoxin, anticoagulants, immunosuppressants, or Ca2+ antagonists ). But we allows the discontinuation of anticoagulants or change the dose and the change of diuretic dose.
- Patients who diagnosed with other etiology of PAH, such as portal hypertension, pulmonary vein occlusive disease, etc.
- Patients who have a history of left heart disease including ischemic heart disease, myocardial infarction, symptomatic coronary artery disease; or trans-channel radionuclide angiography, angiography, or echocardiography as assessed by mean pulmonary capillary wedge pressure (or left ventricular end diastolic volume) ≥ 15 mmHg or left ventricular ejection fraction ≤ 40%; or systemic hypertension that cannot be effectively controlled, systolic blood pressure> 160 mmHg or diastolic blood pressure> 100 mmHg.
- Patients who have a history of lung diseases, including chronic obstructive pulmonary disease, interstitial lung disease, etc.
- Patients who have a history of blood diseases, including a history of coagulation disorders within 6 months before screening.
- Patients who are allergic to two or more drugs or food; or are known to be allergic to one anti-inflammatory drug (steroidal or non-steroidal anti-inflammatory drug).
- Liver function test exceeds or equals 3 times the upper limit of normal or suffering from known Child-Pugh Class C liver disease.
- Patients with chronic renal insufficiency, and the screening creatinine value is greater than 2.5mg/dL (221μmol/L) or need dialysis.
- Patients with other diseases or conditions that can affect the results of the research.
- Patients who participated in other study drugs or medical devices within 30 days before screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Ambrisentan+Sulfasalazine
|
Sulfasalazine is an anti-inflammatory and immunosuppressive drug
Ambrisentan is one of the specific drug therapy for pulmonary arterial hypertension
|
ACTIVE_COMPARATOR: Ambrisentan+Sulfasalazine's placebo
|
Ambrisentan is one of the specific drug therapy for pulmonary arterial hypertension
Sulfasalazine's placebo is similar to Sulfasalazine in form and dosage
|
EXPERIMENTAL: Ambrisentan's placebo+Sulfasalazine
|
Sulfasalazine is an anti-inflammatory and immunosuppressive drug
Ambrisentan's placebo is similar to Ambrisentan in form and dosage
|
PLACEBO_COMPARATOR: Ambrisentan's placebo+Sulfasalazine's placebo
|
Sulfasalazine's placebo is similar to Sulfasalazine in form and dosage
Ambrisentan's placebo is similar to Ambrisentan in form and dosage
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to First Confirmed Clinical Adverse Event up to the End of Treatment
Time Frame: Up to end of treatment (data presented up to month 6)
|
Clinical adverse event was defined as death.
|
Up to end of treatment (data presented up to month 6)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to Month 6 in 6-minute Walk Distance
Time Frame: Baseline to month 6
|
The 6-minute walk test (6MWT) is a non-encouraged test, performed in a 30 m long flat corridor, where the patient is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed.
These guidelines were provided to all sites.
For patients who had never performed a 6MWT previously, a training test was required before the qualifying tests for inclusion were performed.
|
Baseline to month 6
|
Change From Baseline to Month 6 in Inflammation Factor
Time Frame: Baseline to month 6
|
Compose of Interleukin-6
|
Baseline to month 6
|
Change From Baseline to Month 6 in Echocardiography Examination
Time Frame: Baseline to month 6
|
Assessment of pulmonary artery systolic pressure by echocardiography
|
Baseline to month 6
|
Change From Baseline to Month 6 in Cardiac Function
Time Frame: Baseline to month 6
|
Compose of B-type natriuretic peptide
|
Baseline to month 6
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 1, 2020
Primary Completion (ANTICIPATED)
December 31, 2021
Study Completion (ANTICIPATED)
October 31, 2022
Study Registration Dates
First Submitted
August 14, 2020
First Submitted That Met QC Criteria
August 22, 2020
First Posted (ACTUAL)
August 27, 2020
Study Record Updates
Last Update Posted (ACTUAL)
August 27, 2020
Last Update Submitted That Met QC Criteria
August 22, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Hypertension, Pulmonary
- Hypertension
- Pulmonary Arterial Hypertension
- Familial Primary Pulmonary Hypertension
- Physiological Effects of Drugs
- Antihypertensive Agents
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Gastrointestinal Agents
- Sulfasalazine
- Ambrisentan
Other Study ID Numbers
- treatment of PAH
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Arterial Hypertension
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
American Medical Association FoundationWithdrawnIdiopathic Pulmonary Arterial Hypertension.United States
-
Vanderbilt University Medical CenterRecruitingIdiopathic Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial Hypertension | Scleroderma Associated Pulmonary Arterial Hypertension | Appetite Suppressant Associate PAHUnited States
-
Gachon University Gil Medical CenterChonbuk National University Hospital; Samsung Medical Center; Pusan National... and other collaboratorsUnknownPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Deep Phenotyping | Heritable Pulmonary Arterial HypertensionKorea, Republic of
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
Zhejiang UniversityUnknownIdiopathic Pulmonary Arterial HypertensionChina
-
Association de Recherche en Physiopathologie RespiratoireGlaxoSmithKline; Soladis; InterlisUnknownPulmonary Arterial Hypertension (PAH)France
-
Medical University of GrazLudwig Boltzmann Institute for Lung Vascular ResearchCompletedIdiopathic Pulmonary Arterial HypertensionAustria
-
Zhejiang UniversityCompletedIdiopathic Pulmonary Arterial HypertensionChina
-
Regina Steringer-MascherbauerUnknownPulmonary Arterial Hypertension WHO Group IAustria
Clinical Trials on Sulfasalazine
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedDiarrhea | Unspecified Adult Solid Tumor, Protocol Specific | Gastrointestinal ComplicationsUnited States
-
Qiong FuNot yet recruiting
-
The Second Affiliated Hospital of Chongqing Medical...RecruitingFibrosis, Liver | Cirrhosis, LiverChina
-
Karolinska InstitutetHarvard Medical School (HMS and HSDM)Completed
-
Chung Shan Medical UniversityUnknownAnkylosing SpondylitisTaiwan
-
Infectious Diseases Physicians, Inc.Johns Hopkins UniversityCompletedProsthetic Joint Infection | Osteomyelitis | Septic Arthritis | Bone Infection | Joint InfectionUnited States
-
Cairo UniversityActive, not recruitingOral Lichen Planus | Corticosteroids | Topical SulfasalazineEgypt
-
University of NebraskaCompletedRheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingAcute Myeloid LeukemiaFrance
-
Singapore General HospitalTerminatedRheumatoid ArthritisSingapore